Evidence map›Paper›PMID 42782876›Full record

Observational studyCurrent oncology (Toronto, Ont.)2026

Real-World Outcomes of Second-Line Chemotherapy in Metastatic Urothelial Carcinoma.

İlkay Çıtakkul, Hayati Arvas, Mert Karaoğlan, Bahadır Köylü, Nazan Demir, Gözde Balkaya Aykut, Elif Şahin, Mesut Yılmaz, Zuhat Urakçı, Duygu Bayır Garbioğlu and 8 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

İlkay ÇıtakkulDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Türkiye.
Hayati ArvasDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakır 21280, Türkiye.ORCID 0000-0003-2215-5567
Mert KaraoğlanDepartment of Medical Oncology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir 26480, Türkiye.ORCID 0000-0001-5069-685X
Bahadır KöylüDepartment of Internal Medicine, Division of Medical Oncology, School of Medicine, Koç University, Istanbul 34450, Türkiye.ORCID 0000-0002-4462-6393
Nazan DemirDepartment of Internal Medicine, Division of Medical Oncology, School of Medicine, Koç University, Istanbul 34450, Türkiye.ORCID 0009-0000-2988-4450
Gözde Balkaya AykutDivision of Medical Oncology, Ümraniye Training and Research Hospital, Istanbul 34764, Türkiye.
Elif ŞahinDivision of Medical Oncology, Kocaeli City Hospital, Kocaeli 41060, Türkiye.ORCID 0000-0002-1976-3951
Mesut YılmazDepartment of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya 54050, Türkiye.ORCID 0000-0002-1041-9628
Zuhat UrakçıDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakır 21280, Türkiye.
Duygu Bayır GarbioğluDepartment of Medical Oncology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir 26480, Türkiye.ORCID 0000-0001-7347-263X
Fatih SelçukbiricikDepartment of Internal Medicine, Division of Medical Oncology, School of Medicine, Koç University, Istanbul 34450, Türkiye.
Ece BaydarDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Türkiye.ORCID 0000-0001-8527-936X
Beşire Nurdan TazebayDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Türkiye.
Melike YazıcıDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Türkiye.
Yasemin Bakkal TemiDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Türkiye.ORCID 0000-0002-1268-6666
Devrim ÇabukDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Türkiye.ORCID 0000-0002-7871-6311
Kazım UygunDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Türkiye.
Umut KefeliDepartment of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Second-line chemotherapy is widely used in metastatic urothelial carcinoma after progression on first-line platinum-based therapy, but its independent contribution to survival, as opposed to selection of healthier patients, remains unclear. In this multicenter retrospective cohort of 142 patients treated with first-line platinum-based chemotherapy across seven Turkish centers, overall survival (OS) from first-line progression was compared between patients who received second-line chemotherapy (

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic NeoplasmsAgedFemaleHumansMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesTreatment Outcomebladder cancerchemotherapyoverall survivalpropensity scoresecond-line treatmenturothelial cancer

Identifiers

PMID42782876
PMCPMC13605251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.